{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:10:29Z","timestamp":1780110629371,"version":"3.54.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jfma.2025.02.035","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:23:05Z","timestamp":1741101785000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"125","author":[{"given":"Shih-Hung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5503-9266","authenticated-orcid":false,"given":"Chien-Jui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sz-Chi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Fong","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8975-9491","authenticated-orcid":false,"given":"Li-Chun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-887X","authenticated-orcid":false,"given":"Sung-Hsin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-174X","authenticated-orcid":false,"given":"Kun-Huei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.02.035_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(23)00516-8","article-title":"Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients","volume":"25","author":"Gyawali","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jfma.2025.02.035_bib3","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jfma.2025.02.035_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.02.035_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.02.035_bib6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.02.035_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000330817","article-title":"Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials","volume":"81","author":"Yang","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.jfma.2025.02.035_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.02.035_bib9","unstructured":"https:\/\/cris.hpa.gov.tw\/pagepub\/Home.aspx."},{"key":"10.1016\/j.jfma.2025.02.035_bib10","unstructured":"https:\/\/www.mohw.gov.tw\/cp-16-79055-1.html."},{"key":"10.1016\/j.jfma.2025.02.035_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211058255","article-title":"Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study","volume":"13","author":"Chiu","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65689-8","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine\/nab-paclitaxel","volume":"14","author":"Shibuki","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.02.035_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919871126","article-title":"Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group","volume":"11","author":"Yoo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib14","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3390\/curroncol29040216","volume":"29","author":"Yamai","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12885-023-10654-3","article-title":"FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study","volume":"23","author":"Kobayashi","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfma.2025.02.035_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00432-024-05827-x","article-title":"Sequential therapy of refractory metastatic pancreatic cancer with 5-FU\/LV\/irinotecan (FOLFIRI) vs. 5-FU\/LV\/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)","volume":"150","author":"Modest","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100049","article-title":"Liposomal irinotecan plus fluorouracil\/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)","volume":"6","author":"Park","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jfma.2025.02.035_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jfma.2019.01.015","article-title":"Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients","volume":"119","author":"Yang","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.02.035_bib19","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/curroncol28030164","article-title":"Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study)","volume":"28","author":"Giommoni","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib20","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41416-022-01713-w","article-title":"Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study","volume":"126","author":"Zaibet","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2025.02.035_bib21","first-page":"502","article-title":"The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma","volume":"64","author":"Yamaguchi","year":"2020","journal-title":"J Neurosurg Sci"},{"key":"10.1016\/j.jfma.2025.02.035_bib22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/cncr.24179","article-title":"Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma","volume":"115","author":"Chamberlain","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2025.02.035_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1593\/neo.08928","article-title":"Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model","volume":"10","author":"Mathieu","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.jfma.2025.02.035_bib24","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2025.02.035_bib26","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2025.02.035_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1078-0432.CCR-19-1864","article-title":"Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells","volume":"26","author":"Mota Reyes","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2025.02.035_bib28","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-19-2959","article-title":"Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy","volume":"80","author":"Principe","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfma.2025.02.035_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00262-024-03821-3","article-title":"Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma","volume":"73","author":"Yang","year":"2024","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:10:24Z","timestamp":1771488624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0929664625001019"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.02.035","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}